We are investigating Apyx Medical Corporation (APYX) (“Apyx” or the “Company”) for potential violations of the federal securities laws.
On March 16, 2020, Apyx announced that its financial statements for the twelve months ended December 31, 2018 and the quarterly statements for the three and nine months ended September 30, 2018 and three months ended March 31, 2019 could no longer be relied upon and would need to be restated. On this news, Apyx’s stock price fell $0.23 per share, or 5.01%, to close at $4.36 per share on March 17, 2020.